The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic ...

Citigroup initiated coverage on shares of Biogen (NASDAQ:BIIB – Get Free Report) in a report issued on Thursday, MarketBeat ...

Los Angeles Capital Management LLC bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) in the third ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

On Thursday, Biogen Inc (BIIB) stock saw a decline, ending the day at $164.89 which represents a decrease of $-0.90 or -0.54% from the prior close of $165.79. The stock opened at $165 and touched a ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...